Cwm LLC trimmed its holdings in Catalent Inc (NYSE:CTLT) by 26.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 220,093 shares of the company’s stock after selling 79,939 shares during the quarter. Cwm LLC owned 0.15% of Catalent worth $12,391,000 at the end of the most recent reporting period.
A number of other large investors have also bought and sold shares of CTLT. Penn Capital Management Co. Inc. purchased a new stake in Catalent in the second quarter valued at $3,584,000. HighTower Advisors LLC acquired a new position in shares of Catalent in the second quarter worth about $210,000. Man Group plc raised its position in shares of Catalent by 28.7% in the second quarter. Man Group plc now owns 37,485 shares of the company’s stock worth $2,031,000 after acquiring an additional 8,352 shares during the period. Jane Street Group LLC acquired a new position in shares of Catalent in the second quarter worth about $972,000. Finally, UBS Asset Management Americas Inc. raised its position in shares of Catalent by 2.9% in the second quarter. UBS Asset Management Americas Inc. now owns 197,343 shares of the company’s stock worth $10,698,000 after acquiring an additional 5,642 shares during the period.
In related news, COO Alessandro Maselli sold 7,268 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $53.18, for a total transaction of $386,512.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Ricardo Pravda sold 2,612 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $52.73, for a total transaction of $137,730.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,512 shares of company stock valued at $2,921,998. Insiders own 1.30% of the company’s stock.
Shares of Catalent stock opened at $62.00 on Tuesday. The firm has a 50-day simple moving average of $57.01 and a two-hundred day simple moving average of $53.22. The company has a market cap of $9.01 billion, a P/E ratio of 65.96, a price-to-earnings-growth ratio of 2.66 and a beta of 1.69. Catalent Inc has a fifty-two week low of $35.53 and a fifty-two week high of $62.49. The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.65 and a current ratio of 2.06.
Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.19 by $0.07. The business had revenue of $664.70 million during the quarter, compared to the consensus estimate of $634.87 million. Catalent had a net margin of 5.77% and a return on equity of 15.30%. The company’s revenue was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.28 earnings per share. Equities research analysts forecast that Catalent Inc will post 1.78 EPS for the current year.
A number of research analysts have weighed in on the stock. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Stephens upped their price objective on shares of Catalent from $65.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Zacks Investment Research downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $60.57.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Story: Buy Rating
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.